|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] P Cane1, A de Ruiter2, L Navaratne2, P Rice3, M Wiselka4, R Fox5, D Pillay1
1 PHLS ASRU, Birmingham; 2 Guy's and St Thomas' Hospital, 3 St George's Hospital, London; 4 Leicester Royal Infirmary; 5 Gartnavel Hospital, Glasgow, UK
BHIVA Conf 2001 Apr 27-29;7:O8
BACKGROUND: Practically all data on the selection of mutations in HIV-1 associated with the development of resistance to antiretroviral drugs have been derived from studies on subtype B virus. However, subtype C virus is the most prevalent world-wide, and there is increasing evidence of transmission of non-B virus in the developed world, particularly by the heterosexual route. This report describes the variability of HIV-1 protease from PI-experienced and -naïve patients infected with HIV-1 subtype C in the UK.
METHODS: Plasma samples were submitted for routine HIV-1 genotypic resistance testing. Protease gene sequences were analysed for the presence of drug-resistance associated mutations. Subtype designation was based on pol gene sequences and confirmed by analysis of gag and env genes in some cases.
RESULTS: Samples from 51 patients infected with subtype C HIV-1 were analysed. Therapy information was available for 44 patients, including 26 PI-treated and 18 PI-naïve patients. The most common primary mutation observed in the treated patients was L90M (10/26 treated patients compared with 0/18 untreated). G73S, V82A/F and I84V were each observed in two treated patients but only in association with L90M. Although 12 patients had been treated with nelfinavir, D30N was not observed. M36I and I93L have been described as accessory mutations in subtype B HIV-1. These codon changes were observed in most samples from both treated and untreated patients and cannot be considered as resistance-associated mutations in this subtype.
CONCLUSIONS: The spectrum and prevalence of PI-associated resistance mutations differed between subtype B and C viruses. Genotypic resistance data from non-B viruses should be interpreted carefully.
PRESENTING AUTHOR: L Navaratne
010427
O8
Copyright © 2001 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD